Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, has reached an agreement with South Korean company PRG S&T to obtain rights to Progerinin (SLC-D011), an investigational drug for treating Hutchinson-Gilford Progeria Syndrome. Under the agreement, Sentynl will acquire full rights to this FDA-designated orphan drug upon achieving specific milestones, adding a second potential therapy for progeria to its rare disease portfolio. The oral small molecule candidate targets the harmful progeria protein and is currently in Phase IIA clinical trials, with data expected by mid-2026.